An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Pelvic Infections; Infections

Treatments: Drug: Comparator: Ticarcillin/Clavulanate; Drug: MK0826, ertapenem sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092170

2004_062

0826-038

Details and patient eligibility

About

The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections.

Full description

The duration of treatment is 18 months.

Sex: All

Ages: 3 months to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 3 months to 17 years with intra-abdominal infection or acute pelvic infection

Exclusion criteria

• Immune problems
• Kidney problems